Search Results
Feb 11, 2026, 11:57 ET DXC inaugura un Centro de Experiencia del Cliente en Londres para impulsar el valor de la IA
apoyará a algunas de las organizaciones públicas y privadas más importantes de la región, incluidas la Policía Metropolitana, Network Rail, Barts Health NHS Trust, London Market Insurance Companies, el Ministerio de Defensa y el Departamento de Salud y Asistencia Social, permitiéndoles acelerar la transformación
More news about: DXC Technology Company
Feb 11, 2026, 11:54 ET DXC eröffnet Customer Experience Center in London, um den Wert von KI zu erschließen
einige der bedeutendsten öffentlichen und privaten Organisationen der Region unterstützen, darunter die Metropolitan Police, Network Rail, Barts Health NHS Trust, London Market Insurance Companies, das Verteidigungsministerium und das Ministerium für Gesundheit und Soziales, und ihnen dabei helfen, ihre
More news about: DXC Technology Company
Feb 11, 2026, 03:00 ET DXC Launches London Customer Experience Center to Help Unlock AI Value
will support some of the region's most important public and private sector organizations including the Metropolitan Police, Network Rail, Barts Health NHS Trust, London Market Insurance Companies, the Ministry of Defence, and the Department of Health & Social Care, enabling them to accelerate digital
More news about: DXC Technology Company
Feb 11, 2026, 03:00 ET DXC Launches London Customer Experience Center to Help Unlock AI Value
will support some of the region's most important public and private sector organizations including the Metropolitan Police, Network Rail, Barts Health NHS Trust, London Market Insurance Companies, the Ministry of Defence, and the Department of Health & Social Care, enabling them to accelerate digital
More news about: DXC Technology Company
Feb 05, 2026, 13:06 ET New Report by Project InnerSpace Sets Out a Path for Geothermal to Become a Cornerstone of the United Kingdom's Energy System
"This report shows that harnessing the heat beneath our feet—starting with practical deployments through heat networks and anchor customers like the NHS—can lower bills over time, strengthen energy security, and create high-quality jobs across the country. The opportunity is vast, and it's one we can
More news about: Project InnerSpace
Feb 05, 2026, 08:31 ET MEDOME RELEASES SOLUTION TO END MISDIAGNOSIS IN PRIMARY CARE; WILL SAVE 100s OF THOUSANDS OF LIVES ANNUALLY
personalizes guidance based on your health archetype.PROOF IT WORKSValidated by 20,000+ users. Supported by Stanford, Harvard, NIH, and NHS. Already saving lives by catching what doctors missed."Doctors are human. They're overworked. They have fifteen minutes per patient," said Dr.
More news about: Medome
Feb 04, 2026, 10:47 ET Robotic Surgery Market Is No Longer a Technology Story. It Is a Discipline Test for Hospitals: MMR Statistics
as a capacity and risk-management lever. In the United Kingdom (UK), the conversation looks different but no less urgent. With NHS surgical backlogs, constrained capital budgets, and an overstretched workforce, robotic surgery is increasingly framed as a potential efficiency tool
More news about: MMR Statistics
Feb 04, 2026, 09:00 ET PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology
London, Guy's and St Thomas' NHS Foundation Trust and Barts Health NHS Trust in a joint venture that combines clinical expertise, academic leadership and advanced technologies. By leveraging 10x Genomics' Xenium spatial platform, PharosAI intends to transform decades of archived NHS cancer samples into high-resolution,
More news about: 10x Genomics, Inc.
Feb 03, 2026, 11:30 ET Simpplr launches an AI teammate for internal communicators: Meet Comms AI
intuitive, highly extensible, and built to integrate seamlessly with your existing technology. More than 1,000 leading organizations — including AAA, the NHS, Penske, and Moderna — trust Simpplr to foster a more aligned and productive workforce. Headquartered in Silicon Valley with global offices, Simpplr
More news about: Simpplr
Feb 03, 2026, 10:00 ET Flat Medical Secures Strategic Wins in Europe: EpiFaith® Smart Syringe Enters UK NHS Framework and AP-HP France
Partnerships In the UK, Flat Medical partnered with Fannin UK to successfully navigate the rigorous NHS Supply Chain process. This achievement grants EpiFaith® Smart Syringe access to the extensive NHS hospital network and is expected to trigger broader adoption across Europe through the NHS's global
More news about: Flat Medical
Feb 03, 2026, 09:00 ET Kneu Health Recruits Exceptional Leadership Team to Scale Neurodegenerative Care Across U.S. Health Systems
more than a decade of longitudinal research from Oxford and expanded with over 500,000 digital measures from more than 1,400 users across U.S. and UK NHS deployments, Kneu's clinically validated platform analyzes speech, movement, and cognition to generate predictive biomarkers that support earlier detection
More news about: Kneu Health
Feb 03, 2026, 08:04 ET World's First Chief AI Officer and Peak Performance Experts to Take Stage at Healthcare CX Conference
the agenda includes key healthcare leaders from BCBS, NHS, Cognoa, Caresource, Google, and more, who are shaping the future of the industry. Interested parties can
More news about: League Inc.
Jan 30, 2026, 21:52 ET NEUBERGER HIGH YIELD STRATEGIES FUND ANNOUNCES MONTHLY DISTRIBUTION
NEW YORK, Jan. 30, 2026 /PRNewswire/ -- Neuberger High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") has announced a distribution declaration of $0.0905 per share of common stock. The distribution announced today is payable on February
More news about: Neuberger Berman
Jan 29, 2026, 19:25 ET GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
(first year) of the NHS-Galleri trial, the largest, and only, randomized, controlled trial of any MCED test in an intended use population. The submission is also supported by a bridging analysis to compare performance of the version of Galleri used in the PATHFINDER 2 study and the NHS-Galleri trial to
More news about: GRAIL, Inc.
Jan 29, 2026, 09:00 ET The Lancet Publishes TRICORDER Study: Real-World Evaluation Shows Increased Detection When Eko AI-Enabled Stethoscopes Are Used in Primary Care
Large-scale NHS trial led by Imperial College London across 200+ NHS practices shows significant gains in early cardiac disease detection through AI-assisted stethoscope examsSAN FRANCISCO, Jan. 29, 2026 /PRNewswire/
More news about: Eko Health
Jan 29, 2026, 08:00 ET NHS launches a single end-to-end lung cancer diagnostic pathway initiative with Optellum
pleased to announce its selection in a landmark NHS initiative that combines Optellum's AI-driven lung cancer risk stratification with robotic-assisted bronchoscopy in a single, end-to-end diagnostic pathway for lung cancer. Spearheaded by Guy's and St Thomas' NHS Foundation Trust, this programme is designed
More news about: Optellum
Jan 29, 2026, 03:00 ET UK cyber security jobs have tripled since 2021, Socura ONS report reveals
, a cyber security services provider that protects many of the nation's biggest NHS trusts, councils, and private companies, has today published its latest report: 'A wave in cyber'.
More news about: Socura
Jan 28, 2026, 05:38 ET Manipal Hospitals Adopts Harrison.ai's chest X-ray AI to improve patient outcomes
available in 40+ countries and to half of all Australian radiologists. They are clinically deployed at 1,000+ customer sites globally, including 40+ NHS Trusts and all public emergency departments in Hong Kong. With 3,400+ clinicians using our tools, Harrison.ai has impacted more than 7 million patients'
More news about: Manipal Hospitals
Jan 21, 2026, 03:00 ET Infinitopes Expands Seed Financing to $35 Million to Accelerate Clinical Development of Precision Cancer Vaccine
recurrence in oesophageal cancer, an area where clinical need remains largely unmet. The Phase I/IIa VISTA trial is to be conducted across multiple UK NHS university cancer centres and firmly positions Infinitopes at the cutting edge of the sector.Jonathan Kwok, Chief Executive Officer of Infinitopes,
More news about: Infinitopes
Jan 20, 2026, 19:00 ET Rakuten Medical Expands Academic Access to IR700 Dye Through Fee-Only Provision, Greater Publication Freedom and Expanded IP & Commercialization Opportunities
developing and commercializing Alluminox® platform-based photoimmunotherapy, today announced that it will provide IRDye® 700DX N-hydroxy succinimide (NHS) ester (IR700 dye), at an administrative fee-only acquisition cost for academic research with increased flexibility for publication, intellectual property
More news about: Rakuten Medical, Inc.
Jan 20, 2026, 17:31 ET PSMA-Targeted Therapy Market Set to Expand by 2034 on Strong Pipeline and Increasing Diagnosis Rates | DelveInsight
Pharmaceuticals. It consists of rosopatamab, a humanized IgG1 monoclonal antibody, conjugated to the beta-emitting radioisotope lutetium-177 using the DOTA-NHS ester chelator. Also referred to as TLX591, the therapy delivers cytotoxic radiation specifically to PSMA-expressing prostate cancer cells, enabling
More news about: DelveInsight Business Research, LLP
Jan 19, 2026, 10:50 ET H.I.G. Realty en Barts Health NHS Trust lanceren samen het eerste Barts Life Sciences Project
innovatie, de weg van prototype naar patiënt versnelt en de capaciteit van het Verenigd Koninkrijk voor in de NHS ingebedde innovatie vergroot. Shane DeGaris, Group CEO van Barts Health NHS Trust, zegt: "Via het Barts Life Sciences Cluster brengen we clinici, patiënten, de industrie en de academische
More news about: H.I.G. Capital
Jan 19, 2026, 03:00 ET H.I.G. Realty and Barts Health NHS Trust Partner to Launch the First Barts Life Sciences Project
innovation-ready ecosystem that speeds the journey from prototype to patient and enhances the UK's capacity for NHS-embedded innovation. Shane DeGaris, Group CEO of Barts Health NHS Trust, said: "Through the Barts Life Sciences Cluster, we are bringing clinicians, patients, industry, and academia
More news about: H.I.G. Capital
Jan 19, 2026, 03:00 ET H.I.G. Realty und Barts Health NHS Trust starten gemeinsam das erste Barts Life-Sciences-Projekt
geschaffen, das den Weg vom Prototyp zum Patienten beschleunigt und die Fähigkeit des Vereinigten Königreichs zu NHS-integrierten Innovationen verbessert. Shane DeGaris, Group CEO von Barts Health NHS Trust, sagte: „Durch den Barts Life Sciences Cluster bringen wir Kliniker, Patienten, Industrie und Wissenschaft
More news about: H.I.G. Capital
Jan 19, 2026, 03:00 ET H.I.G. Realty and Barts Health NHS Trust Partner to Launch the First Barts Life Sciences Project
innovation-ready ecosystem that speeds the journey from prototype to patient and enhances the UK's capacity for NHS-embedded innovation. Shane DeGaris, Group CEO of Barts Health NHS Trust, said: "Through the Barts Life Sciences Cluster, we are bringing clinicians, patients, industry, and academia
More news about: H.I.G. Capital